Cor Vasa 2008, 50(10):385-392 | DOI: 10.33678/cor.2008.137

Heart failure and atrial fibrillation

Růžena Lábrová*, Jindřich Špinar
Interní kardiologická klinika, Fakultní nemocnice Brno a Lékařská fakulta Masarykovy univerzity, Brno, Česká republika

Heart failure and atrial fibrillation are often referred to as the epidemics of the 21st century. They are conditions characterized by an appreciably increasing incidence with increasing age - the typical patient is over 70 years old. The prerequisite for successful drug therapy of both conditions is effective oral anticoagulation and an individualized choice between rhythm versus rate control in an effort to prevent sudden cardiac death or progression of heart failure. Optimal therapy of heart failure should control symptoms and prevent the onset of new atrial fibrillation. The question whether to control rhythm or rate in the treatment of atrial fibrillation has to date been investigated in patients with preserved left ventricular ejection fraction, that is, those without heart failure. However, some reports have pointed out that maintaining sinus rhythm significantly improves the prognosis of heart failure and prevents its deterioration. Atrioventricular junction ablation with subsequent pacing or, possibly, biventricular pacing, seem to be particularly beneficial in patients with severe heart failure. Ostial ablation or, better still, electrical isolation of pulmonary veins by surgery or radiofrequency ablation is currently the method of choice.

Keywords: Atrial fibrillation; Heart failure; Rhythm control; Rate control; Ablation; Pacing

Published: October 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lábrová R, Špinar J. Heart failure and atrial fibrillation. Cor Vasa. 2008;50(10):385-392. doi: 10.33678/cor.2008.137.
Download citation

References

  1. Cleland JGF, Swedberg K, Follath F, et al. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: Patient characteristics and diagnosis. Eur Heart J 2003;24:442-63. Go to original source... Go to PubMed...
  2. Cowie MR, Mosterd A, Wood MA, et al. The epidemiology of heart failure. Eur Heart J 1997;18:208-25. Go to original source... Go to PubMed...
  3. Fonarow GC for the ADHERE Scientific Advisory Committee: The Acute Decompensated Heart Failure (ADHERE) National registry: Opportunities to improve care of patients hospitalised with acute decompensated heart failure. Rev Cardiovasc Med 2003;4:S21-S30.
  4. Nieminen MS, Boehm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure. Eur Heart J 2005;26: 383-416.
  5. Nieminen M, Brutsert D, Dickstein K, et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalised acute heart failure patients: description of population. Eur Heart J 2006;27:2725-36. Go to original source... Go to PubMed...
  6. Padelleti L, Pieragnoli P, Jentzen V, Schuchert A. The comorbidity of atrial fibrillation and heart failure: a chalenge for eletrical therapies. Eur Heart J 2007;9 (Suppl 1):181-6. Go to original source...
  7. Špinar J, Janský P, Kettner J, Málek I. Doporučení pro diagnostiku a léčbu akutního srdečního selhání. Cor Vasa 2006;48:K3-31.
  8. Špinar J, Hradec J, Meluzín J, et al. Doporučení pro diagnostiku a léčbu srdečního selhání ČKS 2006. Cor Vasa 2007;49:K5-K33.
  9. Špinar J, Aschermann M, Al-Hiti H, et al. Databáze akutního srdečního selhání na specializovaných kardiologických klinikách. Cor Vasa 2008;1:12-22. Go to original source...
  10. Cha YM, Redfield MM, Shen WK, Gersh BJ. Atrial fibrillation and ventricular dysfunction: a vicious elektromechanical cycle. Circulation 2004;109:2839-43. Go to original source... Go to PubMed...
  11. Adams KF Jr., Zannad F. Clinical definition and epidemiology of advanced heart failure. Am Heart J 1998;135: S204-S215. Go to original source... Go to PubMed...
  12. Go AS, Hylek EM, Phiulips KA, et al. Prevalence of diagnosed atrial fibrillation in adults national implications for rhytm management and stroke prevention: the Anticoagulation and Risk factors in Atrial Fibrilation (ATRIA) Study. JAMA 2001;285:2370-5. Go to original source... Go to PubMed...
  13. Lábrová R. Epidemilogie fibrilace síní. Kardiol Rev: Kardiofórum 2007;5:6-10.
  14. Wang TJ, Larson MG, Lewy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality. The Framingham Heart Study. Circulation 2003;107:2920-5. Go to original source... Go to PubMed...
  15. Čihák R, Heinz P. Doporučení pro léčbu fibrilace síní. Cor Vasa 2004;46:K46-K78.
  16. Fuster V, Ryden LE, Asinger RW, at al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. J Am Coll Cardiol 2001; 38:1231-65. Go to original source... Go to PubMed...
  17. Jaïs P, Haïssaguerre M, Shah DC, et al. A focal source of atrial fibrillation treated by discrete radiofrequency ablation. Circulation 1997;95:572-6. Go to original source... Go to PubMed...
  18. Lévy S, Marek M, Coumel P, et al. Characterization of different subsets of atrial fibrillation in general practice in France. The ALFA Study. Circulation 1999;99: 3028-35. Go to original source... Go to PubMed...
  19. Hsu LF, Sanders P, Carrigue S, et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 2004;351:2373-83. Go to original source... Go to PubMed...
  20. Pozzoli M, Cioffi G, Traversi E, et al. Predictors of primary atrial fibrillation and concomitant clinical and haemodynamic changes in patients with chronic heart failure: a prospective study in 344 patients with baseline sinus rhythm. J Am Coll Cardiol 1998;32:197-204. Go to original source... Go to PubMed...
  21. Khand AU, Gemmel I, Rankin AC, Cleland JG. Clinical events leading to the progression of heart failure: insight from national database of hospital discharges. Eur Heart J 2001;22:153-64. Go to original source... Go to PubMed...
  22. Redfield MM, Kay GN, Jenkins LS, et al. Tachycardia-related cardiomypathy: a common cause of ventricular dysfunction in patients with atrial fibrillation referred for atrioventricular ablation. Mayo Clin Proc 2000;75: 790-5. Go to original source... Go to PubMed...
  23. Ludka O, Špinar J, Pozdíšek Z, a spol. Profil nemocného se srdečním selháním hospitalizovaného na interním oddělení. Cor Vasa 2003;45:K 137.
  24. Spinar J, Ludka O, Musil V, et al. The profile and prognosis of patients hospitalised with heart failure; the value of discharge blood pressure and cholesterol. Intern Heart J 2008; v tisku.
  25. Dahlöf B, Devereux RB, Kjeldsen SE, for the LIFE investigators: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoints reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003. Go to original source... Go to PubMed...
  26. Wachtel K, Hornestam B, Lehto M, et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For Endpoints reduction in hypertension (LIFE) study. J Am Coll Cardiol 2005;45:705-11. Go to original source... Go to PubMed...
  27. Wachtel K, Lehto M, Olsen MH, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: Losartan Intervention For Endpoints reduction in hypertension (LIFE) study. J Am Coll Cardiol 2005;45:712-9. Go to original source... Go to PubMed...
  28. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. Guidelines Committee. J Hypertens 2003;21:1011-53.
  29. Widimský J jr., Cífková R, Špinar J, et al. Doporučení diagnostických a léčebných postupů arteriální hypertenze - verze 2007. Doporučení České společnosti pro hypertenzi. Cor Vasa 2008;1:K3-K23.
  30. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhytm control in patients with atrial fibrillation. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. N Engl J Med 2002;347:1825-45 Go to original source...
  31. Špinar J, Vítovec J. Fibrilace síní. Vnitř Lék 2003;49:748-53. Go to PubMed...
  32. The Stroke Prevention in Atrial Fibrilation Investigators. Predictors in thromboembolism in atrial fibrillation. I Clinical features of patients at risk. Ann Intern Med 1992;116:1-5. Go to original source... Go to PubMed...
  33. Lukl J, Heinc P, et al. Moderní léčba arytmií. Praha: Grada Publishing, 2001:173-7.
  34. Wood MA, Brown-Mahoney C, Kay GN, Ellenbogen KA. Clinical outcome after ablation and pacing therapy for atrial fibrillation: a meta analysis. Circulation 2000;101: 1138-44. Go to original source... Go to PubMed...
  35. Sweeney MO, Hellkamp AS, Ellenbogen KA, et al. Adverse effects of ventricular pacing on heart failure and atrial fibrillation among patients with normal QRS duration in clinical trial of pacemaker therapy for sinus node dysfunction. Circulation 2003;107:2932-7. Go to original source... Go to PubMed...
  36. Leon AR, Greenberg JM, Kanuru N, et al. Cardiac resynchronization in patients with congestive heart failure and chronic atrial fibrillation: effect of upgrading to biventricular pacing after chronic right ventricular pacing. J Am Coll Cardiol 2002;39:1258-63. Go to original source...
  37. Brignole M, Gammage M, Puggioni E, et al. Comparative assessment of right, left and biventricular pacing in patients with permanent atrial fibrillation. Eur Heart J 2005;26:712-22. Go to original source... Go to PubMed...
  38. Catanzariti D, Maines M, Cemin C, et al. His bundle pacing does not induce ventricular dyssynchrony unlike conventional right ventricular apical pacing. An intrapatient acute comparison study. J Interv Card Elektrophysiol 2006;16:81-92. Go to original source... Go to PubMed...
  39. Carlson MD, Ip J, Messenger J, et al. Atrial Dynamic Overdrive Pacing Trial (ADOPT) Investigators: A new pacemaker algorhytm for the treatment of atrial fibrillation: results of the Atrial Dynamic Overdrive Pacing Trial (ADOPT). J Am Coll Cardiol 2003;42:627-33. Go to original source... Go to PubMed...
  40. Bardy GH, Lee KL, Mark DB, et al, for the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-37. Go to original source... Go to PubMed...
  41. Linde C. Implantable cardioverter-defibrillator treatment and resynchronisation in heart failure. Heart 2004;90: 231-4. Go to original source... Go to PubMed...
  42. Morgan JM. The MADIT II and COMPANION studies: will they affect uptake of device treatment? Heart 2004; 90:243-5. Go to original source... Go to PubMed...
  43. Moss AJ. MADIT-II and its implications. Eur Heart J 2003;24:16-8. Go to original source... Go to PubMed...
  44. Bax JJ, Abraham T, Barold SS, et al. Cardiac resynchronization therapy, I: issues before device implantation. J Am Coll Cardiol 2005;46:2153-67. Go to original source... Go to PubMed...
  45. Bax JJ, Abraham T, Barold SS, et al. Cardiac resynchronization therapy, II: issues during and after device implantation and unresolved questions. J Am Coll Cardiol 2005;46:2168-82. Go to original source... Go to PubMed...
  46. Bax JJ, Bleeker GB, Marwick TH, et al. Left ventricular dyssynchrony predicts response and prognosis after cardiac resynchronization therapy. J Am Coll Cardiol 2004;44:1834-40. Go to original source... Go to PubMed...
  47. Bradley DJ, Bradley EA, Baughman KL, et al. Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. JAMA 2003;289:730-40. Go to original source... Go to PubMed...
  48. Bristow MR, Saxon LA, Boehmer J, et al, for COMPANION Investigators: Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140-50. Go to original source... Go to PubMed...
  49. Leclercq C, Walker S, Linde C et al, on behalf of the MUSTIC group: Comparative effects of permanent biventriculare and right ventricular pacing in heart failure patients with chronic atrial fibrillation. Eur Heart J 2002;23:1780-7. Go to original source... Go to PubMed...
  50. Gasparini M, Aurichio A, Metra M, et al, for the Multicentre Longitudinal Observation Study (MILOS) Group: Long term survival in patients undergoing cardiac resynchronisation therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrail fibrillation. Eur Heart J 2008;29: 1644-52. Go to original source... Go to PubMed...
  51. Leclercq C, Mabo P. Cardiac resynchronisation therapy and atrial fibrillation. Do we have final answer? Eur Heart J 2008;29:1597-9. Go to original source... Go to PubMed...




Cor et Vasa

You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.